Neurocrine Biosciences (NBIX) Tops Q2 EPS by 127c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $155.64 --0%
Revenue Growth %: +30.8%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +30.8%
Financial Fact:
Research and development: 20.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $2.85, $1.27 better than the analyst estimate of $1.58. Revenue for the quarter came in at $959 million versus the consensus estimate of $877.34 million.
GUIDANCE:
Neurocrine Biosciences sees FY2026 revenue of $2.82-2.87 billion, versus the consensus of $3.79 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'
- NMP and Gibson Technical Services agree to $400M SPAC merger
- Truist on Mohawk Industries (MHK): 'Valuation Does Not Reflect Changing Story on Industry Shifts'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
